Loading company…
Mabworks is a Beijing biopharmaceutical company developing antibody drugs for tumours and autoimmune diseases.
Established in 2003 and based in Beijing, China, Mabworks develops antibody drugs through three technical platforms covering ADCC-enhanced antibodies, multi-specific antibodies, and antibody discovery and optimization. In March 2023 the company was listed on the New Third Board, and in March 2024 it raised CNY 217.99 million in strategic investment from CGP Investment and E-Town International Industrial Investment. In 2022 its revenue was CNY 15.89 million and its net income was CNY -251.85 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in